Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study

S. Gkalpakiotis, M. Arenbergerova, P. Gkalpakioti, J. Potockova, P. Arenberger, P. Kraml,

. 2017 ; 44 (4) : 363-369. [pub] 20161024

Language English Country England, Great Britain

Document type Comparative Study, Journal Article

Psoriasis is a chronic systemic immune-mediated inflammatory dermatosis associated with several comorbidities. Psoriasis patients are at increased risk of developing cardiovascular diseases (CVD), namely, coronary heart disease, stroke or peripheral vascular disease, and psoriasis seems to be an independent cardiovascular risk factor. Antipsoriatic systemic therapy, especially anti-tumor necrosis factor (TNF)-α, seems to exert a beneficial effect on these comorbidities. The purpose of this study was: (i) to measure the level of cardiovascular serum markers in psoriasis patients in comparison with healthy volunteers; and (ii) to compare the serum level of the same markers in patients before and 3 months after adalimumab therapy. We investigated six biomarkers connected to CVD: C-reactive protein (measured high sensitively, hsCRP), oxidized low-density lipoproteins (oxLDL), oxLDL/β-glycoprotein I complex (oxLDL/β2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22. These biomarkers were measured in 21 patients with moderate/severe psoriasis before and after treatment with adalimumab and in healthy volunteers. hsCRP (P < 0.05), oxLDL-β2GPI complex (P < 0.05), E-selectin (P < 0.001) and IL-22 (P < 0.001) were significantly increased in comparison with healthy controls, whereas oxLDL and VCAM-1 were also higher in psoriasis patients but the difference did not reach statistical significance. A decrease of E-selectin (P < 0.001) and IL-22 (P < 0.001) was observed after 3 months of adalimumab therapy. Inhibition of TNF-α seems to not only improve psoriasis but also decreases serum cardiovascular biomarkers. E-selectin and IL-22 could serve for monitoring of the efficacy of antipsoriatic systemic therapy on cardiovascular risk.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031365
003      
CZ-PrNML
005      
20171216103023.0
007      
ta
008      
171025s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/1346-8138.13661 $2 doi
035    __
$a (PubMed)27774694
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gkalpakiotis, Spyridon $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
245    10
$a Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study / $c S. Gkalpakiotis, M. Arenbergerova, P. Gkalpakioti, J. Potockova, P. Arenberger, P. Kraml,
520    9_
$a Psoriasis is a chronic systemic immune-mediated inflammatory dermatosis associated with several comorbidities. Psoriasis patients are at increased risk of developing cardiovascular diseases (CVD), namely, coronary heart disease, stroke or peripheral vascular disease, and psoriasis seems to be an independent cardiovascular risk factor. Antipsoriatic systemic therapy, especially anti-tumor necrosis factor (TNF)-α, seems to exert a beneficial effect on these comorbidities. The purpose of this study was: (i) to measure the level of cardiovascular serum markers in psoriasis patients in comparison with healthy volunteers; and (ii) to compare the serum level of the same markers in patients before and 3 months after adalimumab therapy. We investigated six biomarkers connected to CVD: C-reactive protein (measured high sensitively, hsCRP), oxidized low-density lipoproteins (oxLDL), oxLDL/β-glycoprotein I complex (oxLDL/β2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22. These biomarkers were measured in 21 patients with moderate/severe psoriasis before and after treatment with adalimumab and in healthy volunteers. hsCRP (P < 0.05), oxLDL-β2GPI complex (P < 0.05), E-selectin (P < 0.001) and IL-22 (P < 0.001) were significantly increased in comparison with healthy controls, whereas oxLDL and VCAM-1 were also higher in psoriasis patients but the difference did not reach statistical significance. A decrease of E-selectin (P < 0.001) and IL-22 (P < 0.001) was observed after 3 months of adalimumab therapy. Inhibition of TNF-α seems to not only improve psoriasis but also decreases serum cardiovascular biomarkers. E-selectin and IL-22 could serve for monitoring of the efficacy of antipsoriatic systemic therapy on cardiovascular risk.
650    _2
$a adalimumab $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000068879
650    _2
$a dospělí $7 D000328
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a C-reaktivní protein $x analýza $7 D002097
650    _2
$a kardiovaskulární nemoci $x krev $x komplikace $7 D002318
650    _2
$a dermatologické látky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D003879
650    _2
$a E-selektin $x krev $7 D019040
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a lidé $7 D006801
650    _2
$a interleukiny $x krev $7 D007378
650    _2
$a lipoproteiny LDL $x krev $7 D008077
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pilotní projekty $7 D010865
650    _2
$a psoriáza $x krev $x komplikace $x farmakoterapie $7 D011565
650    _2
$a rizikové faktory $7 D012307
650    _2
$a TNF-alfa $x antagonisté a inhibitory $7 D014409
650    _2
$a cévní buněčněadhezivní molekula-1 $x krev $7 D019010
650    _2
$a beta-2-glykoprotein I $x krev $7 D053482
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Arenbergerová, Monika $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic. $7 xx0074761 $4
700    1_
$a Gkalpakioti, Petra $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Potockova, Jana $u 2nd Department of Internal Medicine, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Arenberger, Petr $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic. $7 nlk19990072992
700    1_
$a Kraml, Pavel $u 2nd Department of Internal Medicine, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
773    0_
$w MED00002635 $t The Journal of dermatology $x 1346-8138 $g Roč. 44, č. 4 (2017), s. 363-369
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27774694 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171102132151 $b ABA008
999    __
$a ok $b bmc $g 1254958 $s 992392
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 44 $c 4 $d 363-369 $e 20161024 $i 1346-8138 $m Journal of dermatology $n J Dermatol $x MED00002635
LZP    __
$a Pubmed-20171025

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...